EHA26: BMS touts positive multiple myeloma data for two pipeline candidates

BMS shared Phase III data for mezigdomide and Phase I data for a CAR-T therapy at this year’s EHA conference. BMS presented trial results from mezigdomide and arlocabtagene autoleucel at EHA 2026. Credit: Tada Images/Shutterstock.com. Bristol Myers Squibb (BMS) has revealed clinical data for two pipeline candidates in multiple myeloma (MM) at the European Hematology Association Congress (EHA) 2026, held from June 11–14. While the drugmaker already has multiple therapies approved for the type of blood cancer, BMS is hoping to expand its presence in the market by addressing certain MM patients with unmet needs. LOA and PTSR Model -…

Source: Clinical Trials Arena